Discovery of multimodal biomarkers for parkinsonian syndromes, their progression, and pathological relevance
Parkinson’s disease and a number of similar conditions, such as progressive supranuclear palsy and multiple system atrophy, often look very similar clinically, particularly early in the disease. Since there is no objective way to diagnose these disorders definitively, the current practice is to follow patients over time to allow the disease to reveal itself. Evidence indicates, however, that even the best movement disorder specialist can provide the wrong diagnosis approximately 25 percent of the time. This lack of diagnostic certainty has limited both clinical practice and research. The goal of this longitudinal study is to determine whether specific MRI and biofluid measures, such as proteins in blood and cerebrospinal fluid, can help better diagnose Parkinson’s, progressive supranuclear palsy and multiple system atrophy patients.
Participants are asked to complete a screening, baseline and 12-month visit. During the baseline and 12-month visit, participants are asked to complete some questionnaires as well as a fasting blood draw, motor evaluation, smell test and MRI. Participants also may choose to complete additional study components that ultimately may guide the diagnosis, prognosis and treatment of Parkinson's and its related disorders. These optional components include skin punch biopsies, a lumbar puncture and participation in the Translational Brain Research Center's brain donation program.
At least 21 years of age
Clinical diagnosis of possible or probable Parkinson's disease (PD), multiple system atrophy (MSA) or progressive supranuclear palsy (PSP)
Inability to participate in the study's required components, such as the fasting blood draw
Major medical problems, such as kidney or liver failure
History of schizophrenia or neuroleptic use